NEW YORK, May 20-Agilent Technologies has signed a licensing agreement for access to Callida Genomics' portfolio of non-universal DNA microarray patents, the two companies said today.
Through the agreement, Agilent will have access to intellectual property protected by a set of patents on the work of Callida CSO Radoje Drmanac, who was involved in early microarray development.
Callida will receive both up-front fees and potential running royalties. The license is non-exclusive.
Callida Genomics, a majority owned subisidiary of Hyseq Pharmaceuticals, was launched last fall following the settlement of a major patent lawsuit between Affymetrix and Hyseq. Researchers at Callida are working to commercialize the sequencing-by-hybridization technology that Drmanac developed.
For more information about this agreement, click here.